Eight months after more than doubling down on its construction of a $2 billion drug manufacturing facility in Holly Springs, ...

Less than a year after the FDA turned down the resubmitted application for the company’s leukemia prospect Dasynoc, Xspray ...

Aurinia Pharmaceuticals has struck a patent infringement settlement with Teva Pharmaceuticals, which should help stave off ...

For patients living with Type 2 diabetes in the United Kingdom, a more convenient treatment option may be on the horizon ...

B. Braun Medical—a maker of IV solutions for hospitals, among other products—has initiated a recall in the United States and ...

Just eight months after it introduced its oral version of semaglutide for obesity, also known as the Wegovy pill, Novo ...

If at first you don’t succeed in gene therapy, then try, try again. | If at first you don’t succeed in gene therapy, then try ...

Boehringer Ingelheim has continued its rise up patient groups’ ranking of rare disease companies, adding to last year’s gains to cement its status toward the top of the leaderboards. | Boehringer ...

After more than 10 years in development, Regeneron secured a landmark approval for its monoclonal antibody garetosmab, now ...

After drafting plans for a phased expansion at its production campus in Swords, Ireland, back in 2022, CDMO SK Pharmteco this ...

After receiving a checkered regulatory scorecard in 2024, Aurobindo’s sterile injectables and oncology unit is back in the ...

In their attempts to challenge the Medicare drug price negotiation program, introduced by former President Joe Biden under ...